Seeking Alpha

Amgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase...

Amgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is the first FDA-approved subcutaneous injection administered every six months. Studies of men with low bone mineral density who took the treatment resulted in significantly greater bone density gains when compared to a placebo.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs